Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Investor Presentation (August 2024)
40 slides from Zydus Lifesciences's investor presentation, Aug 27, 2024
Slide 1: Exchange filing cover letter for investor presentation
August 27, 2024 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai-400 001 Listing Department Code: Zyduslife NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051 Re.: Investor Presentation for Investor Conf
Slide 2: Zydus Lifesciences Limited Investor Presentation
Zydus Lifesciences Limited Investor Presentation August 2024 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Zydus at a Glance
Zydus at a Glance A Leading Lifesciences Player With a Global Footprint Aptly Supported by API Alliances IM ~ US$ 2.35 bn 10% 3% 1% Revenues1 in India Geography 37 FY24 40% Manufacturing facilities FY24 Sales Formulations 28% Consumer Wellness 12% US$ 650 mn Rs. 190,215 EBITDA1 in FY24 mn (27.5% mar
Slide 5: Innovation Updates
Innovation Updates
Slide 6: Innovation at the Core: Moving up the value curve
Innovation at the Core: Moving up the value curve Orphan Disease & Specialty Portfolio through 505(b)(2) NCEs Portfolio of seven 505(b)(2) Biosimilars programs; 3 of them approved. Saroglitazar – World’s first approved Entry into liquid orals space therapy for MASH Leading Indian player with multipl
Slide 7: US Generics Pipeline: Evolving with differentiation
US Generics Pipeline: Evolving with differentiation Transforming the portfolio towards next phase of growth Leveraging the licensing strategy for technically complex products with large opportunity size From To Market NCE-1, First-to-file Focus • Volume-centric • Value centric, differentiated produc
Slide 8: India Portfolio: Value creation through new launches
India Portfolio: Value creation through new launches keeping innovation and affordability at core First-in-India, Day-1 launches and next generation Drug Delivery Multiple initiatives being undertaken towards ensuring access platforms will be one of the key growth drivers and affordability to patien
Slide 9: NCEs and NBEs: Highlights and focus therapy areas
NCEs and NBEs: Highlights and focus therapy Areas NCEs Pipeline Novel Approved Products Drug Lead Pre- Project Target Indication IND Phase I Phase II Phase III NDA Launch Disc. Optim. clinical PBC & PPAR- α:γ Saroglitazar MASH MASH PBC agonist (for US) First NCE Approved/ Launched In India CIA Desid
Slide 10: NCE – Saroglitazar: Liver diseases in PBC and MASH
NCE – Saroglitazar : Leveraging strengths and experience in liver diseases to address unmet medical needs in PBC and MASH indications globally Primary Biliary Cholangitis (PBC) • A rare, progressive auto-immune disease which affects women, Saroglitazar Magnesium with 1 in 1000 women over 40 years of
Slide 11: NCE – Desidustat: First novel oral alternative to injectable ESAs
NCE – Desidustat: First novel oral alternative to injectable ESAs approved in India for anemia in CKD patients ~17% Prevalence of CKD patients in INDIA ~132 Mn People are estimated to be living with CKD in CHINA • Provided relief to over 45000 patients • Granted an exclusive license to the molecule
Slide 12: Biosimilars: Amongst largest players in India
Biosimilars: Amongst largest players in India; increasing reach in Emerging markets Largest biosimilar portfolio and pipeline Domestic market Recent Approvals In India, Zydus is a leading player in 13 biosimilars launched/ approved Oncology Pertuzumab (Approved), Trastuzumab, World’s first biosimila
Slide 13: Vaccines: End-to-end development expertise
Vaccines: End-to-end development expertise 20+ Vaccine innovation comes from two R&D centers focused on developing newer vaccines… Vaccine products in portfolio Multiple types Of offerings Vaccine Technology Centre (VTC) Etna Biotech Ahmedabad, India Catania, Italy • Vaccine R&D center for • R&D cen
Slide 14: Vaccines: Comprehensive portfolio with platform diversity
Vaccines: Comprehensive portfolio with platform diversity Indian company to Indian company to Company globally ü WHO PQ-ed have indigenously In the world to indigenously with an approved 1st developed H1N1 2nd develop Typhoid 2nd develop and launch 1st pDNA vaccine for Rabies vaccine conjugate vacci
Slide 15: Zydus' Innovation Engine is fueled by Centers of Excellence
Zydus’ Innovation Engine is fueled by Centers of Excellence Steady Investment in R&D US$ mn R&D Cost % of Revenues 7.8 7.7 7.2 10 155 6.9 NCE / NBE Research 6.7 8 Formulation Development 135 6 158 115 155 154 151 4 140 95 2 75 0 FY20 FY21 FY22 FY23 FY24 1400+ Scientific Pool Biotech Research Etna Bi
Slide 16: Business Updates
Business Updates
Slide 17: India Formulations: Focus on progressive therapies
India Formulations: Focus on progressive therapies Branded business continues to deliver healthy growth Strong presence in progressive therapy areas India Formulations Sales (Rs. mn) Therapy-wise Break-up of Zydus’ revenues1 10% CAGR Cardio- 53690 Others 48125 49111 (FY20-FY24) Diabeto 14% 40429 15%
Slide 18: India Formulations: Rich brand portfolio to drive growth
India Formulations: Rich brand portfolio to drive growth Increasing contribution of Innovation portfolio Growth Strategies • Among top 5 brands of Zydus1 • Consistent increase in ranking over the years Focused brand building initiatives to scale up more • 40% increase in patient base in FY24 brands
Slide 19: Zydus Wellness: A leading consumer wellness player in India
Zydus Wellness: A leading consumer wellness player in India Building sustainable business over the years Strengthen “Energy” credential with new launches and new consumers • Category leading brand with 99% plus brand recall Consumer Wellness Sales (Rs. mn) • ~ 60% market share1 in the category 7% CA
Slide 20: Zydus Wellness: Strategic initiatives to drive growth
Zydus Wellness: Strategic initiatives to drive growth Focus on category building through volume expansion and recruitment of new consumers; leveraging the innovation to differentiate the offerings Enhance distribution infrastructure and direct coverage; increase direct reach from ~6 lac to ~7 lac st
Slide 21: US formulations: Focused execution powered by a rich portfolio
US formulations: Focused execution powered by a rich portfolio Robust performance backed by comprehensive portfolio Continued investment to build value-centric portfolio US Formulations Sales (Rs. mn) ANDA filings and approvals - ANDA filings and approvals - 9% CAGR FY24 Q1 FY25 86851 (FY20-FY24) 74
Slide 22: US formulations: Expanding presence in the specialty space
US formulations: Expanding presence in the specialty space through in-house development as well as inorganic moves 505(b)(2) portfolio developed in-house Building rare disease portfolio through acquisitions 7 Molecules in pipeline 3 Molecules acquired so far viz. NULIBRY®, Zokinvy® and CUTX101 NDA a
Slide 23: US formulations: Strategic initiatives to drive growth
US formulations: Strategic initiatives to drive growth Continue to file 30-35 ANDAs annually and launch new products to address erosion in base portfolio and grow the business Focus on limited competition/ differentiated/ FTF products to gain competitive advantage (high cashflows) Leverage partnersh
Slide 24: International Markets formulations: Increasing reach
International Markets (IM) formulations: Increasing reach and leveraging global product portfolio progressively Consistent growth through the years Growth Strategies IM Formulations Sales (Rs. mn) Increase the salience of larger brands (known as MDC brands) 16% CAGR in emerging market (EM) countries
Slide 25: JVs and Alliances: Proven track-record of successful partnerships
JVs and Alliances: Proven track-record of successful partnerships Zydus Takeda Healthcare Pvt. Ltd. Zydus Hospira Oncology Pvt. Ltd. • A 50:50 JV with capabilities to manufacture a range of APIs • A 50:50 JV between Zydus and Hospira Inc., USA (now part of and intermediates Pfizer group) to manufact
Slide 26: Manufacturing, Supply Chain and Digitalization Initiatives
Manufacturing, Supply Chain and Digitalization Initiatives
Slide 27: Well supported by a wide network of manufacturing facilities
Well supported by a wide network of manufacturing facilities Ahmedabad Human Formulations Multiple dosages (Moraiya) Oral Solids (SEZ I) India Brazil Myanmar Oral Solids (SEZ II) Sikkim Transdermal (SEZ) Formulations Injectables (SEZ) Topicals (Changodar) Oral Solids (Unit I) Lyophilised Inj. (Vatva
Slide 28: Agile and integrated global supply chain
Agile and integrated global supply chain manages complete value chain from forecasting to demand fulfillment across markets 75+ 4500+ 2500+ 145+ Presence in SKUs being FG (Finished 12+ number of new launches supplied across Goods) batches Dosage Forms per year countries markets demand/ month Key Str
Slide 29: Digital transformation journey (1/2)
Embracing digital transformation journey across functions to generate greater value for all the stakeholders (1/2) Area: Technical Operations Initiatives Features Benefits • Real-time data analytics dashboard through • Quick and clear insight Data Analytics Software - Tableau integration with differ
Slide 30: Digital transformation journey (2/2)
Embracing the digital transformation journey across functions to generate greater value for all the stakeholders (2/2) Area: Supply Chain Initiatives Features Benefits • Advanced data analytics and machine • Detailed insights about demand and Project PACE learning algorithms forecast patterns, produ
Slide 31: Financials
Financials
Slide 32: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) GC (Rs. mn) and Gross Margin % 65.5% 66.7% 63.3% 63.4% 68.1% 74.4% 1,95,474 1,33,192 1,72,374 1,44,035 1,51,099 FY20-FY24 1,09,273 FY20-FY24 1,42,531 96,014 CAGR: 8.2% 93,331 95,647 CAGR: 9.3% Q1 FY25 Gr Q1 FY25 Gr 62075 YoY: 20.8% 46,214 YoY: 33.4
Slide 33: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) Adjusted Net Profit (Rs. mn) Organic Capex (Rs. mn) 37,916 11,218 FY20-FY24 9,579 8,628 26,608 CAGR: 28.2% 7,998 7,634 22,988 20,581 14,028 14,199 Q1 FY25 Gr YoY: 34.9% 3,014 FY20 FY21 FY22 FY23 FY24 Q1 FY25 FY20 FY21 FY22 FY23 FY24 Q1 FY25 Net Debt/ EBITDA Return on Capi
Slide 34: ESG and CSR Updates
ESG and CSR Updates
Slide 35: ESG Initiatives: Fostering the sustainable future
ESG Initiatives: Fostering the sustainable future through the highest standards of environmental stewardship, social responsibility and corporate governance Overview of ESG performance in FY24 ESG Ratings Updates in FY24 FY24 FY23 Variation FY24 FY23 Variation GHG intensity 1 1.57 1.62 3% Corporate
Slide 36: Zydus Srishti: the group's CSR program
Zydus Srishti, the group’s CSR program, has adopted a four pronged approach to make a difference to the society in sync with Sustainable Development Goals SWASTHYA SHIKSHA • Transforms rural healthcare, ensuring access to quality services and promoting well-being. • State of the art science labs at
Slide 37: Awards and Accolades
ESG and CSR Awards Updates and Accolades
Slide 38: Notable Achievements
Notable Achievements Pharma Innovation of the Year Award Pharma Leadership Awards for Bronze Award from IHW Cancer Summit from the Indian Pharma Awards for Excellence in Liver Care, Ayushman liver AWACS 2024 Pharmarack for the Best Brand Most Impactful Cancer Desidustat for most innovative product c
Slide 39: Well diversified board at the helm of the affairs
Well diversified board at the helm of the affairs Pankaj R. Patel Dr. Sharvil P. Patel Ganesh N. Nayak Mukesh M. Patel Managing Director Executive Director Chairman Non-Executive Director Over 2 decades of experience Associated with the group Over 4 decades of experience An advocate and Internationa
Slide 40: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C
Zydus Lifesciences — Investor Presentation (August 2024) on 6ix